MedTrace Logo

Asymmetrical Versus Conventional High-flow Nasal Cannula in Acute Respiratory Failure

NCT06204276 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-04-24

No results posted yet for this study

Summary

The goal of this randomized crossover physiological study is to evaluate the physiologic effects of asymmetrical nasal cannula and conventional nasal cannula in patients with acute respiratory failure. The main questions it aims to answer are:

* Does the asymmetrical high-flow nasal cannula reduce the diaphragm and parasternal intercostal work activity of breathing measured by ultrasound compared to conventional high-flow nasal cannula?
* What is the effect of the asymmetrical high-flow nasal cannula on breathing pattern, gas exchange, and hemodynamic variables compared to conventional high-flow nasal cannula? Participants will received asymmetrical high-flow nasal cannula or conventional high-flow nasal cannula at a flow rate of 40 and 60 L/min in a random order.

Conditions

  • Acute Hypoxemic Respiratory Failure
  • Acute Hypercapnic Respiratory Failure

Interventions

DEVICE

Experimental: Asymmetrical high-flow nasal cannula

Asymmetrical high-flow nasal cannula will be set at 40 and 60 L/min in a random order. Temperature will be set at 37 degree celsius and inspired oxygen fraction (FiO2) will be adjusted to maintain oxygen saturation by pulse oximetry (SpO2) \>/= 94% in acute hypoxemic patients and between 92-94% in acute hypercapnic COPD patients

DEVICE

Active comparator: Conventional high-flow nasal cannula

Conventional high-flow nasal cannula will be set at 40 and 60 L/min in a random order. Temperature will be set at 37 degree celsius and FiO2 will be adjusted to maintain SpO2 \>/= 94% in acute hypoxemic patients and between 92-94% in acute hypercapnic COPD patients

Sponsors & Collaborators

  • Siriraj Hospital

    lead OTHER

Principal Investigators

  • Nuttapol Rittayamai, M.D. · Siriraj Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-20
Primary Completion
2024-11-30
Completion
2024-11-30

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06204276 on ClinicalTrials.gov